Drugs / LIT-00814
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06205082 | Oct 2023 → Oct 2025 | neoplasm | LittDD Medicines Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIT-00814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205082 ↗ |
| Route | Oral | “Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.” NCT06205082 ↗ |